Dostarlimab

Generic Name
Dostarlimab
Brand Names
Jemperli
Drug Type
Biotech
Chemical Formula
-
CAS Number
2022215-59-2
Unique Ingredient Identifier
P0GVQ9A4S5
Background

Dostarlimab is an IgG humanized monoclonal antibody targeted against the human programmed death receptor-1 (PD-1). PD-1 receptors are found on T-cells and, when activated, serve to inhibit immune responses - some cancers leverage this system by overexpressing PD-1 ligands, thereby effectively inhibiting the anti-tumor immune response that would typically att...

Indication

Dostarlimab-gxly is indicated for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer that has progressed despite ongoing or prior treatment with a platinum-containing chemotherapy regimen.
...

Associated Conditions
Advanced Microsatellite Instability High Endometrial Carcinoma, Advanced Mismatch Repair-deficient (dMMR) Endometrial Cancer, Advanced Mismatch repair deficient (dMMR) solid tumors, Recurrent Microsatellite Instability (MSI)-High Endometrial Cancer, Recurrent Mismatch Repair-deficient (dMMR) Endometrial Cancer, Recurrent Mismatch repair deficient (dMMR) solid tumors
Associated Therapies
-
Clinical Trials
Related News

Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM

First Posted Date
2024-10-23
Last Posted Date
2024-10-23
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
4
Registration Number
NCT06655818
Locations
🇰🇷

GSK Investigational Site, Ulsan, Korea, Republic of

A Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal Cancer in China

Phase 2
Recruiting
Conditions
Neoplasms, Rectal
Interventions
Biological: Dostarlimab
First Posted Date
2024-10-15
Last Posted Date
2024-11-05
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
23
Registration Number
NCT06640049
Locations
🇨🇳

GSK Investigational Site, Zhengzhou, China

A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer

Phase 1
Recruiting
Conditions
Melanoma
Interventions
Drug: Cobolimab
Drug: Dostarlimab
First Posted Date
2024-07-26
Last Posted Date
2024-12-20
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
95
Registration Number
NCT06521567
Locations
🇺🇸

GSK Investigational Site, Iowa City, Iowa, United States

Efficacy and Safety Study of Lurbinectedin and Dostarlimab in Cancer Patients: Protocol VHIO21001 - LiDer

Phase 1
Not yet recruiting
Conditions
Endometrial Cancer
Interventions
Drug: Lurbinectedin
Drug: Dostarlimab
First Posted Date
2024-04-26
Last Posted Date
2024-05-10
Lead Sponsor
Vall d'Hebron Institute of Oncology
Target Recruit Count
15
Registration Number
NCT06385548

Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers

Phase 2
Not yet recruiting
Conditions
MMR-D/MSI-H Colorectal Cancers
Interventions
Drug: Niraparib
Drug: Dostarlimab
First Posted Date
2024-04-15
Last Posted Date
2024-08-07
Lead Sponsor
Ibrahim Halil Sahin
Target Recruit Count
20
Registration Number
NCT06365970
Locations
🇺🇸

UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI

First Posted Date
2024-03-27
Last Posted Date
2024-07-26
Lead Sponsor
UNICANCER
Target Recruit Count
120
Registration Number
NCT06333314
Locations
🇫🇷

Hôpital Saint-Antoine, Paris, Île-de-France, France

🇫🇷

Institut de Cancérologie de l'Ouest, Saint-Herblain, France

🇫🇷

Institut du Cancer Avignon-Provence, Avignon, France

and more 18 locations

A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer

First Posted Date
2024-03-19
Last Posted Date
2024-05-20
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
36
Registration Number
NCT06317311
Locations
🇯🇵

GSK Investigational Site, Tokyo, Japan

A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

Phase 3
Recruiting
Conditions
Neoplasms, Head and Neck
Interventions
Drug: Dostarlimab
Drug: Placebo
First Posted Date
2024-02-13
Last Posted Date
2024-07-29
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
864
Registration Number
NCT06256588
Locations
🇬🇧

GSK Investigational Site, Wolverhampton, United Kingdom

Dostarlimab and Cobolimab in Advanced Cervical Cancer

First Posted Date
2024-02-02
Last Posted Date
2024-07-26
Lead Sponsor
Meghan Shea
Target Recruit Count
66
Registration Number
NCT06238635
Locations
🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100

Phase 1
Recruiting
Conditions
Ovarian Clear Cell Carcinoma
Interventions
Drug: Dostarlimab
Drug: LB-100
First Posted Date
2023-10-04
Last Posted Date
2024-08-28
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
21
Registration Number
NCT06065462
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy